Login to Your Account

VBI takes aim at global HBV market with phase III Sci-B-Vac program

By Marie Powers
News Editor

Wednesday, July 12, 2017

As promised last year during its merger with Scivac Therapeutics Inc., VBI Vaccines Inc. is seeking to move Sci-B-Vac, a third-generation hepatitis B virus (HBV) vaccine licensed in Israel and 14 other countries, onto the world stage.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription